IT1110460B
(it)
*
|
1977-03-02 |
1985-12-23 |
Ciba Geigy Ag |
Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
|
FR2639942B1
(fr)
*
|
1988-12-02 |
1991-03-29 |
Sanofi Sa |
Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
|
US5665756A
(en)
*
|
1994-08-03 |
1997-09-09 |
Hoechst Marion Roussel, Inc. |
Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
AU6776196A
(en)
*
|
1995-08-16 |
1997-03-12 |
Eli Lilly And Company |
Potentiation of serotonin response
|
IN182588B
(en:Method)
|
1998-05-12 |
1999-05-08 |
Sun Pharmaceutical Ind Ltd |
|
IE990406A1
(en)
|
1999-05-20 |
2000-12-27 |
Elan Corp Plc |
Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
|
IN186677B
(en:Method)
|
1999-11-12 |
2001-10-20 |
Sun Pharmaceutical Ind Ltd |
|
WO2001078721A1
(en)
*
|
2000-04-13 |
2001-10-25 |
Mayo Foundation For Medical Education And Research |
Aβ42 LOWERING AGENTS
|
US20080021085A1
(en)
*
|
2000-04-13 |
2008-01-24 |
Mayo Foundation For Medical Education And Research |
Method of reducing abeta42 and treating diseases
|
WO2001080845A2
(en)
*
|
2000-04-24 |
2001-11-01 |
Aryx Therapeutics |
(2-aminoethyl) oxime derivatives for the treatment of depression
|
US7256191B2
(en)
*
|
2000-04-24 |
2007-08-14 |
Aryx Therapeutics |
Materials and methods for the treatment of depression
|
CA2462903C
(en)
*
|
2001-10-12 |
2011-09-20 |
Serenix Pharmaceuticals, Llc |
Beta-lactamyl vasopressin v1a antagonists
|
JP4625637B2
(ja)
|
2002-02-22 |
2011-02-02 |
シャイア エルエルシー |
活性物質送達系及び活性物質を保護し投与する方法
|
WO2004071431A2
(en)
*
|
2003-02-05 |
2004-08-26 |
Myriad Genetics, Inc. |
Method and composition for treating neurodegenerative disorders
|
KR20060040676A
(ko)
*
|
2003-07-11 |
2006-05-10 |
미리어드 제네틱스, 인크. |
알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
|
ATE449633T1
(de)
|
2003-09-12 |
2009-12-15 |
Pfizer |
Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
|
ATE473967T1
(de)
*
|
2003-11-26 |
2010-07-15 |
Pfizer Prod Inc |
Aminopyrazolderivate als gsk-3-inhibitoren
|
ES2515092T3
(es)
|
2003-12-11 |
2014-10-29 |
Sunovion Pharmaceuticals Inc. |
Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
US20050233010A1
(en)
*
|
2004-04-19 |
2005-10-20 |
Satow Philip M |
Lithium combinations, and uses related thereto
|
WO2005108683A1
(en)
*
|
2004-04-29 |
2005-11-17 |
Keystone Retaining Wall Systems, Inc. |
Veneers for walls, retaining walls and the like
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020853A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
CA2601709C
(en)
|
2005-03-22 |
2017-02-14 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamylalkanoic acids
|
JP2008538573A
(ja)
|
2005-04-22 |
2008-10-30 |
ワイス |
ベンゾフラニルアルカナミン誘導体およびその5−ht2cアゴニストとしての使用
|
AR056979A1
(es)
*
|
2005-04-22 |
2007-11-07 |
Wyeth Corp |
Derivados de dihidrobenzofuranos y usos de los mismos
|
US20060252825A1
(en)
*
|
2005-04-22 |
2006-11-09 |
Wyeth |
Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
|
US7402687B2
(en)
|
2005-04-22 |
2008-07-22 |
Wyeth |
Dihydrobenzofuran derivatives and uses thereof
|
CA2614289A1
(en)
*
|
2005-07-08 |
2007-01-18 |
Braincells, Inc. |
Methods for identifying agents and conditions that modulate neurogenesis
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
PL1910346T3
(pl)
*
|
2005-07-19 |
2019-09-30 |
Azevan Pharmaceuticals, Inc. |
Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny
|
NZ564789A
(en)
*
|
2005-07-22 |
2010-07-30 |
Myriad Genetics Inc |
High drug load formulations and dosage forms
|
AU2006304787A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
EP1942879A1
(en)
|
2005-10-31 |
2008-07-16 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
FR2912057B1
(fr)
*
|
2007-02-07 |
2009-04-17 |
Sanofi Aventis Sa |
Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
AU2007231011A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
New therapeutic combinations for the treatment of depression
|
JP4615470B2
(ja)
*
|
2006-03-29 |
2011-01-19 |
卓郎 簑和田 |
大脳の認知力を用いた疾患治療・予防の方法および医薬
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
US7678808B2
(en)
|
2006-05-09 |
2010-03-16 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
EP2021000A2
(en)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
US20080033045A1
(en)
*
|
2006-07-07 |
2008-02-07 |
Myriad Genetics, Incorporated |
Treatment of psychiatric disorders
|
TW200817003A
(en)
*
|
2006-07-31 |
2008-04-16 |
Sanofi Aventis |
Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
|
EP2068872A1
(en)
|
2006-09-08 |
2009-06-17 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
WO2008034032A2
(en)
*
|
2006-09-14 |
2008-03-20 |
Azevan Pharmaceuticals, Inc. |
Beta-lactam cannabinoid receptor modulators
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
US20080167363A1
(en)
*
|
2006-12-28 |
2008-07-10 |
Braincells, Inc |
Modulation of Neurogenesis By Melatoninergic Agents
|
EP2125017A2
(en)
*
|
2007-01-11 |
2009-12-02 |
Braincells, Inc. |
Modulation of neurogenesis with use of modafinil
|
US20110034565A1
(en)
|
2008-04-18 |
2011-02-10 |
University College Dublin, National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
US20100092479A1
(en)
*
|
2008-08-18 |
2010-04-15 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
PT2491038T
(pt)
|
2009-10-23 |
2016-07-14 |
Janssen Pharmaceutica Nv |
Octahidropirrolo[3,4-c]pirrolos disubstituídos como modeladores de recetores de orexina
|
JP5815552B2
(ja)
|
2009-12-08 |
2015-11-17 |
ケース ウェスタン リザーブ ユニバーシティCase Westernreserve University |
眼疾患を治療する化合物および方法
|
ES2858499T3
(es)
|
2010-07-01 |
2021-09-30 |
Azevan Pharmaceuticals Inc |
Compuestos para su uso en el tratamiento de trastorno explosivo intermitente
|
BR112013023810A2
(pt)
|
2011-03-17 |
2016-12-13 |
Lupin Ltd |
composições farmacêuticas de liberação controlada de inibidores seletivos da recaptação de serotonina
|
KR101427221B1
(ko)
*
|
2012-08-29 |
2014-08-13 |
주식회사 에스텍파마 |
플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
|
WO2014178064A2
(en)
*
|
2013-04-03 |
2014-11-06 |
Zcl Chemicals Limited |
"an improved process for the preparation of fluvoxamine maleate"
|
CN106456578B
(zh)
|
2014-02-07 |
2020-02-18 |
匈牙利科学院大学及其他机构附属研究所 |
Sigma-1受体激动剂化合物的用途
|
SG10202001065SA
(en)
|
2014-03-28 |
2020-04-29 |
Azevan Pharmaceuticals Inc |
Compositions and methods for treating neurodegenerative diseases
|
MY197558A
(en)
|
2016-03-10 |
2023-06-23 |
Janssen Pharmaceutica Nv |
Methods of treating depression using orexin-2 receptor antagonists
|
US12239125B2
(en)
|
2016-11-24 |
2025-03-04 |
SigmaDrugs Kutató Korlátolt Felelsség Társaság |
Compositions for organ preservation
|
EP3681871A4
(en)
|
2017-09-15 |
2021-05-26 |
Azevan Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF A BRAIN DAMAGE
|
KR20220049526A
(ko)
|
2019-07-19 |
2022-04-21 |
바이오엑셀 테라퓨틱스 인코포레이티드 |
비-진정성 덱스메데토미딘 치료 양생법
|
US11806334B1
(en)
|
2023-01-12 |
2023-11-07 |
Bioxcel Therapeutics, Inc. |
Non-sedating dexmedetomidine treatment regimens
|